Idarubicin Accord (Idarubicin Hydrochloride)

Idarubicin intercalates into DNA and stabilizes the topoisomerase II‑DNA complex, preventing the re‑ligation of DNA strands. This leads to accumulation of double‑strand breaks, inhibition of replication, and apoptosis of malignant cells.

The dosing regimen for Idarubicin Accord is determined by the prescribing oncologist based on the patient’s diagnosis, disease stage, body surface area, and overall health. Specific dose calculations are not provided here.

Safety data for idarubicin in pregnancy and lactation are limited. It is generally avoided unless the potential benefit to the mother outweighs the possible risk to the fetus or infant. Consultation with a specialist is essential.

To request Idarubicin Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Idarubicin is structurally related to daunorubicin and doxorubicin but has a higher lipophilicity, allowing better cellular uptake and potentially greater potency. Compared with other anthracyclines, it may have a slightly different toxicity profile, especially regarding cardiac effects, but overall class‑related risks remain similar.

Idarubicin Accord should be stored at 2‑8 °C in a refrigerator, protected from light. The product must not be frozen or shaken, and it should remain in its original packaging until preparation for intravenous administration.

Idarubicin Accord is supplied as a sterile powder for reconstitution. After proper dilution with an appropriate intravenous solution, it is administered by slow intravenous infusion under the supervision of qualified healthcare professionals.

The most serious risks include cardiotoxicity (potential heart failure), severe myelosuppression leading to infection or bleeding, and rare but life‑threatening hypersensitivity reactions. Continuous monitoring of cardiac function and blood counts is essential during therapy.

Patients with pre‑existing severe cardiac disease, uncontrolled infections, or known hypersensitivity to idarubicin or other anthracyclines should not receive Idarubicin Accord. Additionally, it is contraindicated in individuals where the risk outweighs the therapeutic benefit, as determined by the treating physician.